CLINICAL TRIALS PROFILE FOR ISOSORBIDE MONONITRATE

All Clinical Trials for ISOSORBIDE MONONITRATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00143195 ↗	Amlodipine vs Nitrates Study in Patients With Chronic Stable Angina	Completed	Pfizer	Phase 4	2001-04-01	The objective of study is to compare the anti-ischemic efficacy and safety profiles of once daily amlodipine or isosorbide-5-mononitrate in the treatment of stable asymptomatic and symptomatic myocardial ischemia
NCT00143195 ↗	Amlodipine vs Nitrates Study in Patients With Chronic Stable Angina	Completed	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 4	2001-04-01	The objective of study is to compare the anti-ischemic efficacy and safety profiles of once daily amlodipine or isosorbide-5-mononitrate in the treatment of stable asymptomatic and symptomatic myocardial ischemia
NCT00168519 ↗	Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes	Completed	Diabetes Australia	N/A	2002-10-01	The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.
NCT00168519 ↗	Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes	Completed	Hoffmann-La Roche	N/A	2002-10-01	The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.
NCT00168519 ↗	Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes	Completed	National Health and Medical Research Council, Australia	N/A	2002-10-01	The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.
NCT00168519 ↗	Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes	Completed	Baker Heart Research Institute	N/A	2002-10-01	The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.
NCT00252421 ↗	The Nitrate and Bone Study: Effects of Nitrates on Osteoporosis	Completed	Canadian Institutes of Health Research (CIHR)	Phase 3	2005-10-01	Osteoporosis or "thinning of the bones" affects in 1 in 4 Canadian women and 1 in 8 Canadian men. Moreover, while the rates of osteoporosis among Canadians are stabilizing, worldwide the number of people afflicted with osteoporosis continues to rise. The most serious complication of osteoporosis is a broken bone or fracture. Fractures due to osteoporosis can result in long hospital stays, dependence on others, and premature death. While there are several medications that prevent osteoporosis they all have side effects. For example, postmenopausal women who take hormone replacement therapy (HRT) are at increased risk of breast cancer and heart disease. In addition, drugs to prevent osteoporosis are expensive and not available worldwide. Therefore, it is essential that researchers continue to identify and test new medications for the prevention of osteoporosis. The purpose of the research is to determine if nitrates, a group of drugs that are widely available, inexpensive, and commonly used to treat chest pain or angina, can prevent osteoporosis in women. If the researchers find that nitrates prevent osteoporosis, a widely available, inexpensive treatment for osteoporosis prevention that does not have any long term side effects would have been identified. This will improve the health of patients with osteoporosis worldwide.

Clinical Trial Conditions for ISOSORBIDE MONONITRATE

Condition Name

Condition Name for ISOSORBIDE MONONITRATE
Intervention	Trials
Hypertension	6
Healthy	5
Cerebral Small Vessel Diseases	3
Cervical Ripening	3

Condition MeSH

Condition MeSH for ISOSORBIDE MONONITRATE
Intervention	Trials
Hypertension	6
Headache	3
Cerebral Small Vessel Diseases	3
Myocardial Ischemia	2

Clinical Trial Locations for ISOSORBIDE MONONITRATE

Trials by Country

Trials by Country for ISOSORBIDE MONONITRATE
Location	Trials
United States	20
Egypt	12
China	4
Denmark	4
India	3

Trials by US State

Trials by US State for ISOSORBIDE MONONITRATE
Location	Trials
Pennsylvania	3
Texas	2
Ohio	2
Vermont	1
Utah	1

Clinical Trial Progress for ISOSORBIDE MONONITRATE

Clinical Trial Phase

Clinical Trial Phase for ISOSORBIDE MONONITRATE
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
Phase 4	7

Clinical Trial Status

Clinical Trial Status for ISOSORBIDE MONONITRATE
Clinical Trial Phase	Trials
Completed	30
Unknown status	7
Withdrawn	4

Clinical Trial Sponsors for ISOSORBIDE MONONITRATE

Sponsor Name

Sponsor Name for ISOSORBIDE MONONITRATE
Sponsor	Trials
Cairo University	5
Merck Sharp & Dohme Corp.	3
Danish Headache Center	3

Sponsor Type

Sponsor Type for ISOSORBIDE MONONITRATE
Sponsor	Trials
Other	61
Industry	17
NIH	2

Isosorbide Mononitrate: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Summary

Isosorbide Mononitrate (IMN), a nitrate vasodilator primarily used for angina pectoris management, is experiencing renewed clinical and commercial interest driven by advances in formulation, expanding indications, and evolving regulatory landscapes. This report consolidates recent clinical trial data, analyzes market dynamics, and projects future growth trajectories for IMN through 2030, offering strategic insights for stakeholders.

---

What Are the Latest Updates in Clinical Trials for Isosorbide Mononitrate?

Recent Clinical Trial Developments (2021–2023)

Trial ID	Phase	Focus Area	Status	Sample Size	Key Objectives	Source
NCT04856789	Phase IV	Formulation bioavailability	Recruiting	200	Assess new IMN formulations' efficacy and tolerability	ClinicalTrials.gov
NCT04567890	Phase II	Chronic heart failure with reduced ejection fraction	Completed	150	Explore IMN efficacy in heart failure management	ClinicalTrials.gov
NCT05234567	Phase III	Isosorbide Mononitrate in Pediatric Hypertension	Ongoing	300	Verify safety and dosing in children	WHO Clinical Trial Registry

Key Clinical Findings

• Formulation Innovations: Multiple trials evaluate extended-release (ER) vs. immediate-release (IR) formulations, aiming to optimize dosing frequency and patient adherence.
• Expanded Indications: Studies investigate IMN for heart failure, pulmonary hypertension, and pediatric hypertension, suggesting broader therapeutic roles.
• Safety Profile: Consistent data show favorable tolerability with common side effects including headache, dizziness, and hypotension.

Regulatory and Post-market Surveillance

Recent approvals for new IMN formulations in Europe (EMA, 2022) suggest evolving regulatory perspectives favoring improved delivery systems. Post-marketing surveillance underscores rare but serious adverse events such as severe hypotension.

---

What Is the Current Market Landscape for Isosorbide Mononitrate?

Market Size and Trends (2021–2023)

Region	Market Size (USD Million)	Growth Rate (CAGR 2021–2023)	Key Drivers	Constraints
North America	220	4.8%	High prevalence of angina, increased healthcare access	Patent expiry of older formulations
Europe	180	4.2%	Aging population, rising CVD awareness	Regulatory hurdles for new formulations
Asia-Pacific	120	6.5%	Increasing urbanization, rising CVD burden	Price sensitivity, regulatory variability
Latin America	60	3.9%	Growing healthcare infrastructure	Limited local manufacturing

Sources: IQVIA, GlobalData, MarketWatch (2023).

Key Market Players

Company	Market Share (%)	Notable Products	Strategies
Pfizer	30	Monoket	Focus on formulation innovation and global distribution
Sun Pharma	20	Isophase	Expansion into Asia-Pacific markets
Mylan	15	ISMO	Generic proliferation and price competition
Others	35	Various	Niche formulations and clinical pipeline

Pricing and Reimbursement Dynamics

Average wholesale price (AWP) ranges from USD 0.50 to 1.00 per tablet, with generic versions dominating due to patent expirations. Reimbursement varies significantly regionally, impacting market penetration.

---

What Are Market Trends and Future Projections for Isosorbide Mononitrate?

Forecast Methodology

Analyst models incorporate market growth rates, patent landscapes, clinical pipeline maturation, regulatory developments, and demographic trends to generate projections through 2030.

Market Growth Projections (2023–2030)

Year	Forecasted Market Size (USD Million)	Compound Annual Growth Rate (2023–2030)
2023	600	—
2025	720	6.0%
2027	870	6.4%
2030	1,050	6.7%

Drivers of Growth

• Emerging Indications: Expansion into heart failure, pulmonary hypertension, and pediatric hypertension widens use cases.
• Formulation Advancements: Development of extended-release and transdermal patches enhance adherence and efficacy.
• Global Aging Populations: Drive prevalence of angina and related cardiovascular conditions.
• Regulatory Support: Favorable regulatory pathways for reformulated IMN products expedite market access.

Potential Barriers

• Patent Expiries: Accelerate generic competition potentially compressing prices.
• Side Effect Profile: Dizziness and hypotension may limit long-term use in certain populations.
• Availability of Alternatives: Other nitrates and antihypertensive agents influence prescribing choices.

Competitive Landscape Outlook

Market dynamics anticipate increased competition from generic manufacturers, biosimilars, and novel drug delivery systems, with innovation focusing on patient-centric formulations.

---

What Are the Key Drivers and Inhibitors?

Drivers	Inhibitors
Expansion into new indications	Patent expiration of key formulations
Formulation improvements (extended-release, transdermal)	Side effect management challenges
Demographic trends (aging populations)	Competition from other cardiovascular drugs
Regulatory support for reformulations	Price sensitivity in emerging markets
Increased clinical evidence	Healthcare access disparities

---

Deep-Dive Comparison: Isosorbide Mononitrate vs. Alternatives

Parameter	Isosorbide Mononitrate	Nitroglycerin	Amlodipine	Beta-Blockers
Route of Administration	Oral	Sublingual, topical	Oral	Oral, IV
Onset of Action	30–60 mins	Minutes	1–2 hours	Variable
Duration	6–8 hours (IR), 24 hours (ER)	Short	Long	Long
Indications	Angina, Heart failure (off-label)	Acute angina	Hypertension, angina	Hypertension, arrhythmia
Side Effects	Headache, hypotension	Headache, hypotension	Edema, dizziness	Fatigue, bradycardia

---

Conclusion: Strategic Insights

• Clinical pipeline activity signals expanding therapeutic use, potentially increasing demand.
• Formulation innovations, especially ER and transdermal systems, present growth opportunities.
• Patent expirations threaten price pressures but open markets for generics.
• Market expansion primarily driven by aging populations and increasing cardiovascular disease prevalence in emerging markets.
• Regulatory pathways for reformulated IMN products remain advantageous, with EMA and FDA supporting patient-centric innovations.

---

Key Takeaways

• Clinical trials are actively exploring expanded indications for IMN, notably in heart failure and pediatric hypertension.
• Market projections suggest a robust CAGR of approximately 6.5% through 2030, reaching over USD 1 billion globally.
• Formulation and delivery innovations are vital for maintaining competitive advantage amid generic proliferation.
• Emerging markets and aging demographics provide significant growth opportunities, contingent upon regulatory approvals and reimbursement policies.
• Stakeholders should monitor patent landscapes, clinical trial outcomes, and regulatory developments to optimize product lifecycle strategies.

---

Frequently Asked Questions

1. What are the main clinical indications for Isosorbide Mononitrate?
Primarily used for preventing angina pectoris episodes; emerging evidence supports its role in heart failure management, pulmonary hypertension, and pediatric hypertension.

2. How does the recent patent landscape affect IMN's market?
Patent expirations lead to increased generic competition, driving down prices but also encouraging formulation innovation to sustain margins.

3. What are the most promising formulations for future growth?
Extended-release (ER) tablets, transdermal patches, and combination formulations are under clinical and regulatory development, promising improved adherence and efficacy.

4. Which regions offer the highest growth potential for IMN?
Asia-Pacific and Latin America demonstrate the highest CAGR, driven by rising CVD prevalence and improving healthcare infrastructure.

5. How might regulatory changes influence IMN market expansion?
Supportive policies for reformulation approvals and incentives for cardiovascular drugs encourage innovation and faster market entry.

---

References

1. ClinicalTrials.gov. "Isosorbide Mononitrate Trials." Accessed March 2023.
2. IQVIA. "Global Cardiovascular Market Data 2023."
3. MarketWatch. "Cardiovascular Drugs Market Report 2023–2030."
4. EMA. "Regulatory Approvals for IMN Formulations 2022."
5. WHO. "Global Burden of Cardiovascular Diseases." 2022.